May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy

Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization

Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more

Different vectors lead to comparable improvements in bleeding in Phase III studies

Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more

CSL is setting a $3.5 million price for the first hemophilia B gene therapy to reach the market

Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales

Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more

uniQure and partner CSL to submit regulatory applications next half

Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized